NASDAQ:KITE (KITE) (KITE) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free KITE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$179.79▼$179.7950-Day Range N/A52-Week Range$39.82▼$179.99VolumeN/AAverage Volume1.65 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (KITE) alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About (KITE) Stock (NASDAQ:KITE)Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… KITE Stock News HeadlinesApril 24, 2024 | msn.comFree kite festival is coming to Morro BayApril 24, 2024 | msn.comGo Fly A Kite At Graf Park: Prizes, Food Trucks, MoreApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 24, 2024 | theguardian.comA kite festival and horses bolt in London: photos of the day – WednesdayApril 24, 2024 | finanznachrichten.deShandong Office of Hong Kong Business Daily: A 100 meter long Weifang kite rises in the sky of FranceApril 24, 2024 | msn.comREVIEW: 'The Kite Runner' at Liverpool PlayhouseApril 22, 2024 | msn.comKite Day 2024 In New Rochelle's Davenport ParkApril 22, 2024 | yahoo.comGreenup's Kite Day wild and windyApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 20, 2024 | msn.comDozens of kites to fill Lee’s Summit skies for upcoming Mega-Kite FestivalApril 20, 2024 | msn.comThe Skies Fill with Color at a Chinese Kite FestivalApril 20, 2024 | msn.comAP Photos: The skies fill with color at a Chinese kite festivalApril 19, 2024 | msn.comFree 420 concert, kite festival and more happening in Denver this weekendApril 19, 2024 | yahoo.comDisney on Ice, Kite Fest, Tom Green: Best things to do in, around Lexington this weekendApril 19, 2024 | msn.comLOOK: Filipino Influencer Makes A Kite Out Of Bills Worth $20,000, Prompts InvestigationApril 18, 2024 | 6sqft.comSoar into spring with free kite flying and live music at Brooklyn Bridge ParkApril 18, 2024 | msn.comGo fly a kite ... for mental healthApril 17, 2024 | msn.comBan on kite flying: LHC issues notices to Punjab govt, IGPApril 17, 2024 | msn.comThis week in Kansas City: ‘Ted Lasso’ funnyman at Kauffman Center, plus kite festivalApril 15, 2024 | msn.comAustin kite fest flies high at Zilker ParkApril 15, 2024 | msn.comAustin hosts 96th Kite Fest with shopping, food, and other activitiesApril 14, 2024 | msn.comGo fly a kite! Thousands turn out for iconic Austin festivalApril 14, 2024 | msn.comBenjamin Franklin's Kite Experiment: Why The French Thought He Invented ElectricityApril 13, 2024 | msn.comLubbock Kite Flight held at Mackenzie Park to memorialize children killed in GazaApril 13, 2024 | msn.comCARD postpones Kite Day due to inclement weatherApril 12, 2024 | msn.comThings to do in Denver: Kite festival, wine walk and moreApril 11, 2024 | msn.comThings to do in the Austin area this weekend: Moontower Comedy Festival, ABC Kite Fest and moreSee More Headlines Receive KITE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2017Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:KITE CUSIPN/A CIK1510580 Webwww.kitepharma.com Phone+1-310-8249999FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesArie S. BelldegrunExecutive Chairman of the Board, President, Chief Executive Officer, FounderPaul L. JenkinsonChief Financial OfficerCynthia M. ButittaChief Operating OfficerDavid Chang M.D. Ph.D.Executive Vice President - Research and Development, Chief Medical OfficerHelen S. KimExecutive Vice President - Business DevelopmentTimothy L. MooreExecutive Vice President - Technical OperationsChristine CassianoSenior Vice President - Corporate Communications and Investor RelationsBio & Compensation - Jian Irish Ph.D.Senior Vice President - Supply ChainBio & Compensation - Jeffrey Wiezorek M.D.Senior Vice President - Clinical DevelopmentShawn Cline TomaselloChief Commercial OfficerMore Executives KITE Stock Analysis - Frequently Asked Questions How were (KITE)'s earnings last quarter? (KITE) (NASDAQ:KITE) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating the consensus estimate of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to analyst estimates of $5.74 million. The business's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.54) earnings per share. What other stocks do shareholders of (KITE) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (KITE) investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), Juno Therapeutics (JUNO), Array Technologies (ARRY) and bluebird bio (BLUE). This page (NASDAQ:KITE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (KITE) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
